Correspondence
This section is populated with a variety of content produced by HLC. This includes but is not limited to materials and correspondence that HLC has produced in its communication efforts with Congress on the various issues of interest to our members and their companies as well as affiliated coalitions, campaigns, task force groups as well as documents from testimony before Congress.
April
- HLC responds to CMS Maternal and Infant Health Care in Rural Communities RFI
- HLC comments on CMS CY 2021 and 2022 Policy and Technical changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicaid Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly.
March
- HLC Letter to CMS on access to Chimeric Antigen Receptor (CAR) T-cell therapies.
- Group letter to Senate leadership expressing support for S. 3539 to exempt telehealth services from certain high deductible health plan rules
- Group letter to the Federal Communications Commission requesting immediate action to adapt the Lifeline program to meet the COVID-19 crisis.
- Group letter in support of funding the White House Office of National Drug Control Policy
- Joint Association COVID-19 letter
- HLC Comments on ONC’s 2020-2025 Draft Federal Health IT Strategic Plan
- Group letter on strengthening telehealth for COVID-19
- Group letter to Senate Appropriations in support of HL7 FHIR® standards-related activities for interoperability
- HLC statement to the U.S. Senate Committee on Homeland Security & Governmental Affairs hearing on “The Federal Interagency Response to the Coronavirus and Preparing for Future Global Pandemics.”
- HLC statement to the U.S. House of Representatives Committee on Science, Space, & Technology hearing on “Coronaviruses: Understanding the Spread of Infectious Diseases and Mobilizing Innovative Solutions.”
- HLC statement to the U.S. House of Representatives Subcommittee on National Security and Subcommittee on Economic and Consumer Policy hearing on “U.S. Biodefense and Response to the Novel Coronavirus Outbreak.” This is the Oversight Reform Letter
- HLC statement to the U.S. House of Representatives Committee on Homeland Security hearing on “Confronting the Coronavirus: The Federal Response.”
- HLC responds to HHS Notice of Beneficiary Payment and Parameters proposed rule.
- HLC comments to CMS Medicare Advantage Advance Notice.
- Group Letter in Support H.R. 5741
- Joint Stakeholder Medicare Plan Finder Letter.
- HLC statement to the U.S. Senate Committee on Health, Education, Labor & Pensions hearing on “An Emerging Disease Threat: How the U.S. Is Responding to COVID-19, the Novel Coronavirus.”
- Group letter in support of re-introduction of the “Protecting Jessica Grubb’s Legacy Act.”
- HLC statement to the House Committee on Energy and Commerce Subcommittee on Health for their hearing “Combatting an Epidemic: Legislation to Help Patients with Substance Use Disorders.”
- HLC Comments on the FDA’s “Importation of Prescription Drugs” proposed rule.
February
- Group letter to U.S. Senate in support of the Older Americans Act
- HLC Supports H.R. 5741, the “Strengthening Innovation in Medicare and Medicaid Act”
- HLC response to CMS NPRM on Medicaid Fiscal Accountability Regulation
- HLC letter to the National Clinical Care Commission on policies, effectiveness, and limitations related to prevention and treatment of diabetes.
- HLC letter to Senate Special Committee on Aging hearing on “Home Health Care in Rural America”
- HLC statement to the House Committee on Ways & Means Subcommittee on Health hearing “More Cures for More Patients: Overcoming Pharmaceutical Barriers.”
- HLC written testimony to House Committee on Veterans’ Affairs Subcommittee on Technology Modernization hearing “Data Privacy and Portability at VA: Protecting Veterans’ Personal Data.”
January 2020
- HLC Comments on the Transparency in Coverage Proposed Rule
- HLC support letter to House Energy Commerce Committee on legislation to Improve Americans’ Healthcare Coverage and Outcomes
- HLC letter to CMS on Scope of Practice Recommendations
December 2019
- HLC Letter to EC on Universal Healthcare Coverage (002)
- HLC comments in response to the CMS Physician Self-Referral (Stark Law) Proposed Rule
- HLC Comments in response to the OIG Anti-Kickback Statute and Civil Monetary Penalty Proposed Rule
- HLC applauds the Senate Judiciary Committee for holding the hearing titled “Tackling the Opioid Crisis: A Whole-of-Government Approach.”
- HLC responds to HHS PreventionX RFI
- HLC Comments on Cures 2.0 Request for Information
- Group letter encouraging the Administration to share its views with Congress on the impact of lifting the Patient ID ban
- Group letter to U.S. Senate in support of S. 2892, the Opioid Workforce Act
- Confidentiality Coalition letter to the U.S. Senate Committee on Commerce, Science, and Transportation on “Examining Legislative Proposals to Protect Consumer Data Privacy.”
November 2019
- Letter to House Ways and Means Committee in response to their Rural and Underserved Communities Health Task Force RFI
- Letter in response to CMS RFI on Program Integrity
- Letter to the House Small Business Committee hearing on “Upskilling the Medical Workforce: Opportunities in Health Innovationn
- Group letter to Senate Finance Committee urging long-term reauthorization of PCORI
- Group letter to the leadership of the House Energy & Commerce and Ways & Means Committees urging long-term reauthorization of PCORI
October 2019
- Group letter urging Congress to support delay of the Health Insurance Tax (HIT).
- Letter to the Senate Committee on Finance for the “Treating Substance Misuse in America: Scams, Shortfalls, and Solutions” hearing.
- HLC comments on several bills being considered by the Health, Education, Labor, Pensions Committee
- HLC comments on the Health Resources and Services Administration’s RFI on Rural Access to Health Care Services
- HLC comments on SAMHSA’s Confidentiality of Substance Use Disorder Patient Records Proposed Rule
- HLC’s comments on Development of a CMS Action Plan to Prevent Opioid Addiction and Enhance Access to Medication-Assisted Treatment
September 2019
- HLC Comments on the CY 2020 Hospital OPPS Proposed Rule
- CY 2020 Hospital Outpatient PPS Group Letter
- Medical Device Tax Repeal Group Letter
- Letter to the House Education and Labor Subcommittee on Health, Education, Labor, and Pension’s hearing “Making Health Care More Affordable: Lowering Drug Prices and Increasing Transparency.”
- HLC Letter on CMS’s Proposed Rule, “Medicare Program; Specialty Care Models to Improve Quality of Care and Reduce Expenditures.”
- HLC letter to Bipartisan Policy Center on recommendations to improve rural health
August 2019
- HLC comments in response to ASPE’s RFI: Ensuring Patient Access and Effective Drug Enforcement
- HLC comments in response to FCC notice of proposed rule on “Promoting Telehealth for Low-Income Consumers”
- HLC Letter in support of the “Telehealth Innovation and Improvement Act” (H.R.4013)
- HLC Letter in support of the “Telehealth Innovation and Improvement Act” (S.773)
- Letter in response to CMS RFI on “Reducing Administrative Burden to put Patients over Paperwork”
- HLC comments in response to CMS notice of proposed rule on “Nondiscrimination in Health and Health Education Programs or Activities”
July 2019
June 2019
- Group letter to Congressional Leaders in support of the utilization of Real Time Benefit Tools
- Group letter to House Ways and Means in support of H.R. 3414, the “Opioid Workforce Act of 2019”
- Letter to Ways and Means in support of the full committee health legislation markup
- Group Letter in Support of H.R. 3436 which removes cost-sharing responsibilities for chronic care management services under the Medicare program
- Group letter in support of the Treat and Reduce Obesity Act (S.595/H.R.1530)
- Letter to the House Oversight and Government Reform Committee’s hearing “Medical Experts: Inadequate Federal Approach to Opioid Treatment and the Need to Expand Care.”
- HLC Comments on CMS’s NPRM FY 2020 Inpatient Prospective Payment System
- The Confidentiality Coalition submits commits on ONC’s Trusted Exchange Framework and Common Agreement (TEFCA) Draft 2
- Group letter to the U.S. House of Representatives in support of an amendment to the Labor-HHS appropriations bill to allow for a full range of patient matching solutions
- W&M letter on Pathways to Universal Health Coverage
- Group letter to Congressional Leaders on Binding Arbitration
- Letter to House Energy and Commerce Committee and Ways and Means Committee on draft proposal to modernize Medicare’s Part D prescription drug program.
- HLC Comments on The Lower Health Care Costs Act of 2019 Discussion Draft
- Letter to House Energy and Commerce Committee on “Investing in America’s Healthcare”
- Confidentiality Coalition comments in response to the Centers for Medicare and Medicaid Services’ Notice of Proposed Rulemaking on interoperability and patient access
- Confidentiality Coalition comments in response to the Office of the National Coordinator for Health Information Technology’s Notice of Proposed Rulemaking on interoperability and information blocking
- HLC comments in response to the Centers for Medicare and Medicaid Services’ Notice of Proposed Rulemaking on interoperability and patient access
- HLC comments in response to the Office of the National Coordinator for Health Information Technology’s Notice of Proposed Rulemaking on interoperability and information blocking
May 2019
- Letter to the Senate Special Committee on Aging hearing on “Aging and Disability in the 21st Century: How Technology Can Help Maintain Health and Quality of Life.”
- Friends of PCORI Reauthorization House Support Letter
- Friends of PCORI Reauthorization Senate Support Letter
- Letter to the House Budget Committee on Key Design Components and Considerations for Establishing a Single-Payer Health Care System
- Letter to the Senate Committee on the Judiciary hearing on “Intellectual property and the Price of Prescription Drugs, Focusing on Balancing Innovation and Competition.”
- Letter to the Senate Finance Committee hearing on “”Medicare Physician Payment Reform After Two Years, Focusing on Medicare Access and CHIP Reauthorization Act Implementation and the Road Ahead.”
- Confidentiality Coalition letter to the House Energy and Commerce Committee hearing on “Oversight of the Federal Trade Commission: Strengthening Protections for Americans’ Privacy and Data Security”
- RFI to CMS on Increasing consumer choice through the sale of individual health insurance coverage across state lines through healthcare choice compacts
April 2019
- Letter to House Rules Committee expressing concerns for H.R. 1384, Medicare-For-All Act of 2019
- Confidentiality Coalition letter to U.S. Senate in support of S. 1012 the “Protecting Jessica Grubb’s Legacy Act
- Confidentiality Coalition letter to U.S. House of Representatives in support of H.R. 2062 the “Overdose Prevention and Patient Safety Act
- HLC letter to the U.S. House in support of H.R. 2207, the “Protect Medical Innovation Act”
- HLC Letter to the U.S. Senate in support of S. 692, the “Protect Medical Innovation Act”
- HLC letter in support of S. 1012 the “Protecting Jessica Grubb’s Legacy Act”
- HLC letter in support of H.R. 2062 the “Overdose Prevention and Patient Safety Act”
- Group letter to HHS Inter-Agency Task Force on best practices in pain management
- HLC’s Comments to the Telehealth Request for Information in the 116th Congress
March 2019
- Group letter to Congress in support for the Pandemic and All-Hazards Preparedness & Advancing Innovation Act (PAHPAI, H.R. 269).
- HLC responds to Senator Warner’s request for answers on what healthcare entities are doing to protect patient information and essential operations from cyberattacks
- Letter responding to Senator Lamar Alexander’s request for recommendations to help address America’s rising healthcare costs
- Confidentiality Coalition letter to Senate Commerce Committee on Policy Principles for a Federal Data Privacy Framework in the United States
- Confidentiality Coalition letter to House Energy and Commerce Committee on Protecting Consumer Privacy in the Era of Big Data
- Letter to the House Energy and Commerce Committee on Lowering the Cost of Prescription Drugs Reducing Barriers to Market Competition
- Group letter to Congress in support of FY2020 NDPP Funding
- Group letter to Congress in support for Expanding Access to DSMT
- Letter to U.S. House of Representatives in support of H.R. 1398 to repeal the Health Insurance Tax
- Letter to Senate Committee on Aging on The Complex Web of Prescription Drug Prices
- Letter to Energy and Commerce Committee on Legislative ways to Strengthen Our Health Care System
- Response to the 2020 Medicare Advantage and Part D Advance Notice and Draft Call Letter
- Group letter to Senate Health, Education, Labor and Pensions (HELP) committee on reducing healthcare cost
- Group letter to CMS on recommendations to improve Medicare Diabetes Prevention Program (MDPP)
- Group sign on letter to HHS, Office of Disease Prevention and Health Promotion on Healthy People 2030
February 2019
- Group letter to Congress in support of the Special Diabetes Program
- Letter to Senator Cassidy and Senator Warner the on draft version of the Patient Affordability, Value and Efficiency Act
- Letter to Ways and Means Committee on The Cost of Rising Prescription Drug Prices
- Confidentiality Coalition letter in response to the HHS Office for Civil Rights’ HIPAA RFI
- Group Letter to the FDA on revisiting the 2008 CVOT Guidance
- HLC-BPC Interoperability Report – Advancing Interoperability, Information Sharing,
and Data Access: Improving Health and Healthcare for Americans - Letter to Senate Health, Education, Labor and Pensions Committee on the “Managing Pain During the Opioid Crisis” hearing.
- Letter to Education and Labor Committee on Examining Threats to Workers with Pre-existing Conditions
January 2019
- Letter to Ways and Means Committee on Protecting Pre-existing Conditions
- Letter to Senate Finance on Drug Pricing in America: A Prescription for Change, Part I
- Letter to House Oversight and Reform on Examining the Actions of Drug Companies in Raising Prescription Drug Prices
- Letter to U.S. Senators in support of S.172, The Health Insurance Tax Relief Act
- Letter to the ONC on the draft Strategy on Reducing Burden Relating to the Use of Health IT and EHRs
- Group letter in Support of Protecting Patient Access to Medication
- Confidentiality Coalition Letter in response to the National Institute of Standards and Technology’s RFI on Developing A National Privacy Framework
- Comment letter to the Centers for Medicare and Medicaid Services on the Medicare Advantage and Part D Flexibility Proposed Rule
December 2018
- Comment letter to the Department of Health and Human Services, and Centers for Medicare and Medicaid Services on the International Pricing Index Model for Part B Drugs.
- Letter to the Department of Homeland Security on Inadmissibility on Public Charge Grounds proposed rule
- Multistakeholder Letter urging Congress to Permanently Repeal the Medical Device Tax
November 2018
- Group letter in support of S. 3496, the Improving Seniors Access to Quality Benefits Act.
- Group letter in support of S. 3497, the Medicare Advantage Quality Payment Relief Act.
- Group letter to Senate Leadership urging them to bring the OPPS Act to the Senate floor for a vote during lameduck
- Better Medicare Alliance Group Letter Urging Delay of Health Insurance Tax through 2020
- Confidentiality Coalition Letter to Federal Communications Committee on modernizing the Telephone Consumer Protection Act
- Surgeon General’s Call to Action “Community Health and Prosperity” Comment Letter
- Confidentiality Coalition Letter in response to the National Telecommunications and Information Administration’s RFC on Developing the Administration’s Approach to Consumer Privacy
October 2018
- Letter in response to OIG RFI on Anti-Kickback Statute
- Confidentiality Coalition Letter to Senate Committee on Commerce, Science, and Transportation Hearing on Consumer Data Privacy
- Letter to Senate Committee on Aging on Patient-Focused Care: A Prescription to Reduce Health Care Costs
- Group Letter to Leadership in Support of Opioid Package Agreement
September 2018
- Letter to Senate Health, Education, Labor and Pensions (HELP) Committee on Health Care in Rural America: Examining Experiences and Costs
- Group Letter to House Leadership in Support of Opioid Package Agreement
- Group letter to Leadership urging inclusion of the Overdose Prevention and Patient Safety (OPPS) Act in a final opioid package
- Letter to U.S. Senators supporting their consideration of additional legislation addressing the nation’s opioid crisis
- Diabetes Advocacy Alliance Comments on the 2019 Medicare Physician Fee Schedule Proposed Rule
August 2018
- Letter in response to CMS RFI on Stark law
- Letter to Healthcare Innovation Caucus
- Group letter to Congress in Support of Value-Based Delivery and Payment Models
- Letter to House Energy and Commerce Committee on Examining State Efforts to Improve Transparency of Healthcare Costs for Consumers.
July 2018
- Letter to House Energy and Commerce Committee in support of markup of H.R. 6378
- Letter to Senate Health, Education, Labor and Pensions (HELP) Committee on Reducing Healthcare Costs: Decreasing Administrative Spending Hearing.
- Better Medicare Alliance Allies Letter in Support of H.R. 4952
- Group letter Urging Delay of the Health Insurance Tax Through 2020
- Letter to House Ways & Means Committee on Health Savings Account Mark-up
- Letter to HHS on the Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
- Letter in Response to HHS RFI on Healthcare Sector Innovation and Investment Workgroup
- Group letter to Senate Finance Committee on Access to Telehealth for Opioid Treatment
- Letter to House Ways and Means Committee on Stark Law Hearing
June 2018
- Group letter to CMS supporting expansion of Medicare Diabetes Prevention Program (MDPP)
- Group Letter in Support of U.S. House Legislative Efforts to Address Drug Crisis
- Letter on Consumer-Directed Health Plans Hearing
- Letter to the Joint Economic Committee on Health Savings Accounts
- Letter to House Energy and Commerce Committee on the Pandemic and All-Hazards Preparedness Act (PAHPA)
- Group Letter on Medicare Advantage Participation in Advanced Alternative Payment Models
May 2018
- Group letter to House and Senate Appropriations Committees on Patient Matching
- Obesity Care Advocacy Network Letter in Support of Nominations to the National Clinical Care Commission
- Letter to Senate Finance Committee on Rural Healthcare
- Letter on the Children’s Hospital Graduate Medical Education Program
- Letter to the Senate Health, Education, Labor, and Pensions Committee on the Healthcare Workforce
- Letter to House Energy and Commerce Committee on H.R. 5795, Overdose Prevention and Patient Safety (OPPS) Act
- Letter to House Ways and Means Committee on Health Innovation Hearing
- Group Letter to CMS on Virtual Diabetes Prevention Program in Medicare
- Letter to House Ways and Means Committee on the Medicare Advantage Hearing
Letter to Senate Health, Education, Labor, and Pensions Committee on PAHPA Reauthorization
- Letter to House Energy and Commerce Committee on H.R. 3545, Overdose Prevention and Patient Safety (OPPS) Act
April 2018
- Patient Access to Pharmacists’ Care Coalition letter to the Energy & Commerce Committee on efforts to address the opioid epidemic
- Group Letter in Support of H.R. 4841 and Electronic Prior Authorization
- Confidentiality Coalition Letter on H.R. 4613, Ensuring Patient Access to Healthcare Records of 2017 – House Energy and Commerce Committee
- Confidentiality Coalition Letter on H.R. 4613, Ensuring Patient Access to Healthcare Records of 2017 – House Ways and Means Committee
- Confidentiality Coalition Letter on H.R. 4613, Ensuring Patient Access to Healthcare Records of 2017 – Senate HELP Committee
March 2018
- Diabetes Advocacy Alliance Letter to the Centers for Medicare and Medicaid Services on Diabetes Self-Management Training
- Letter on Price Transparency
- Obesity Care Advocacy Network Letter on US Preventive Services Task Force Obesity Recommendations
- HLC Letter to House Ways and Means Committee Hearing on the Implementation of MACRA’s Physician Payment Policies
- Letter to Medicaid and CHIP Payment and Access Commission on Substance Use Disorder Confidentiality Regulations and Care Integration in Medicaid
- Letter to US House of Representatives on 42 C.F.R. Part 2
- Letter to US Senate on 42 C.F.R. Part 2
- Group Letter on Individual Health Insurance Market Stabilization and Reinsurance
- Response to the 2019 Medicare Advantage and Part D Advance Notice and Draft Call Letter
- Letter on Reducing Red Tape in Medicare
February 2018
- Letter on OIG Solicitation of Safe Harbors
- Letters on the Preventive Health Savings Act
- Letter in Support of the State Offices of Rural Health Reauthorization Act
- Council for Affordable Health Coverage Letter on Health Insurance Market Stabilization
- Red Tape List of Reforms to Reduce Regulatory Burden
- Comment Letter on FDA’s New Strategic Policy Roadmap
- Letter on TEFCA Framework to ONC
- Letter in Support of the Medicaid Coverage for Addiction Recovery Expansion Act
- Letter in Support of the Good Samaritan Health Professionals Act
- Group Letter Urging Permanent Reauthorization of the Medicare Advantage Special Needs Plans
- Group Letter Urging Passage of Medicare Extenders Package
January 2018
- Letter to House Ways and Means Committee on the Opioid Crisis
- Letter to the Senate Health, Education, Labor, and Pensions Committee on Public Health Preparedness
- Response to the Department of Health and Human Services’ Request for Information on Promoting Choice and Competition Across the United States
- Letter Supporting Electronic Prior Authorization in Medicare Part D
- Letter to Senate Finance Committee on Health Savings Accounts
- Comments on the Proposed Policy Changes and Updates for the Medicare Advantage and Part D Prescription Drug Programs for 2019
- Letter Urging Repeal of the medical device tax and Health Insurance Tax
- Alex Azar Finance Committee letter
December 2017
- Group Letter Urging Extension of Safety Net Programs
- Letter to the House Ways and Means Committee on the Affordable Care Act’s Taxes and Mandates
- Coalition for Affordable Health Coverage Letter on the Senate Health, Education, Labor, and Pensions Committee Hearing on the Cost of Prescription Drugs
- Comments to the Food and Drug Administration on Regulatory Reform
- Group Thank You Letter on Funding for the Centers for Disease Control and Prevention
November 2017
- Letter in Support of the Preventive Health Savings Act
- Letter of Support for Alex Azar’s nomination as HHS Secretary (HELP Committee)
- HLC’s response to CMS’ Request for Information on the Center for Medicare and Medicaid Innovation
- Response to the 2019 Notice of Benefit and Payment Parameters
- Statement of Commitment to Clinician Well-Being and Resilience
- Letter to Senator Gardner on the Health Insurance Tax
- Letter to Senator Hatch on the Medical Device Tax
- Letter to Representative Paulsen on the Medical Device Tax
- Letter in Support of Legislation on the Section 1332 State Innovation Waivers
- Diabetes Advocacy Alliance Response to the Center for Medicare and Medicaid Innovation Request for Information
- Letter to Senate Health Education, Labor, and Pensions Committee on the Hearing on Healthy Communities
October 2017
- Coalition to Promote Independence in Medicare Letter in support of the Community-Based Independence for Seniors Act
- Obesity Care Advocacy Network Letter to the United States Pharmacopeia on the New Class for Anti-Obesity Agents
- Letter Urging the Inclusion of Telehealth Provisions in Upcoming Legislation
- Group Letter on the CHRONIC Care Act
- Diabetes Advocacy Alliance Comments on the Department of Health and Human Services Strategic Plan for 2018-2022
- Comments on the Department of Health and Human Services Strategic Plan for 2018-2022
- Comments to the Medicaid and CHIP Payment and Access Commission
- Letter in Support of S. 1978, the Small Business and Family Health Tax Relief Act
- Letter to Senate Health, Education, Labor, and Pensions Committee on the October 19 Wellness Hearing
- Letter to Acting Secretary Hargan on the National Clinical Care Commission Act
- Letter on the Community-Based Independence for Seniors Act
- Letter to Senator Gardner on the Health Insurance Tax Relief Act
- Letter to the Senate Finance Committee on the Children’s Health Insurance Program
- Letter to the House Energy and Commerce Committee on Public Health Programs
September 2017
- Stakeholder Comments to CMS on the Virtual Medicare Diabetes Prevention Program
- Letter to CMS on Concerns Related to Payment for Biosimilar Biological Products
- Campaign to End Obesity Action Fund Letter in Support of the Childhood Obesity Research Demonstration Program
- Stakeholder Letter to CMS Encouraging the Inclusion of Virtual Diabetes Prevention Program Providers
- Letter in Support of Delaying the Health Insurance Tax
- Letter on the Healthcare Workforce
- HLC Comments on W&M Medicare
- HLC Comments on E&C Health Subcommittee
- Diabetes Advocacy Alliance Letter on the Medicare Physician Fee Schedule and the Diabetes Prevention Program
- Diabetes Advocacy Alliance Letter on the Preventing Diabetes in Medicare Act
- Letter on Extending Safety Net Programs
- Letter to the Senate Finance Committee on the Children’s Health Insurance Program
- Letter to Senate Finance Committee on Health Reform
- Letter to Senate Health, Education, Labor, and Pensions Committee on Health Reform
August 2017
- Response to the Request for Information on Medicare Flexibility and Efficiency
- Letters to Senators Heller and Nelson on the Resident Physician Shortage Act
- HLC Comments on W&M Red Tape Initiative
- HLC Comments on CY18 QPP
- OPPS Act Letter of Support
July 2017
- Special Needs Plan Coalition Letter to Energy and Commerce Committee
- Letter to the House Ways and Means Committee On Its Markup of HR 3178 and HR 3168
- Letter in Support of the Nomination of Dr. Jerome Adams to be Surgeon General
- Letter in Support of the Patient Choice and Quality Care Act
- Letter to the Energy and Commerce Committee on the Medicare Advantage Special Needs Plans
- Diabetes Advocacy Alliance Letter on the Preventive Health Savings Act
- Letters in Support of the Personal Health Investment Today Act
- Response to the Department of Health and Human Services’ Request for Information on Reducing Regulatory Burdens Imposed by the Patient Protection and Affordable Care Act
- Diabetes Advocacy Alliance Letter on Funding for Diabetes Programs
June 2017
- Diabetes Advocacy Alliance Letter on the Medicare Diabetes Prevention Program
- Letter on the Alternative Payment Model Framework RefreshLetter on the State Children’s Health Insurance Program and the Federally Qualified Health Centers
- Letter to the Ways and Means Committee on Medicare Advantage
- Senate Health Reform Statement
- Medicaid Principles
May 2017
- Letter on Alternative Payment Models in Medicare Advantage
- Letter to Administrator Verma on Healthcare Common Procedure Coding System Codes
- Letter to Chairman of the Senate Committee on FinanceLetter to Representatives Crowley and Costello in Support of the Resident Physician Shortage Reduction Act
- Letter to Ways and Means Committee on Medicare Hearing
- Reforms to Regulations that will Improve Care Delivery and Lower Costs
- Letter on Medicare Advantage and Alternative Payment Models
- HLC Letter on the Medical Product Communications Act (H.R.1703)
- Letter in Support of CONNECT for Health Act
April 2017
- Letter to Senate HELP Committee Opposing Drug Importation
- Letter in Support of the National Clinical Care Commission Act
- Letter to Congressional Leadership on the Cost Sharing Reduction Subsidies
- Letter in Response to the Medicare Transformative Ideas Request for Information
- Letter in support of the CHRONIC Care Act
- Letter to Secretary Price on Market Stabilization
- FY1718 Labor-H Patient Matching Report Langauge Support Letter v FINAL
March 2017
- Letter on Education and Workforce March 1 hearing
- Comments on the Lower Drug Costs through Competition Act
- Medicare Advantage Call Letter Response
- Letter on the Market Stabilization Rule
- Letter to Chairman Walden and Chairman Brady on the AHCA
- Diabetes Advocacy Alliance Letter to Secretary Price
- Diabetes Advocacy Alliance Letter in support of National Diabetes Prevention Program funding
February 2017
- National Osteoporosis Foundation Letter on Non Interference
- Partnership for Safe Medicines letter to Congress
- Judiciary Protecting Access to Care Act
- Protect Patient Access to Medication Group Letter on Non-Interference
- SAMHSA SNPRM Rule Partnership Comments
- Group Letter in Support of IPAB Repeal
- Letter of Support for Seema Verma’s nomination as CMS Administrator
- Letter of Support for the Saving Lives, Saving Costs Act of 2017
- Letter to Small Business Committee on their Healthcare Hearing February 7
- Letter to Energy and Commerce Committee on exchanges
- Letter to Health, Education, Labor, and Pensions Committee on stabilizing the individual market
January 2017
- Comments to the National Quality Forum on the African American Heart Failure eMeasure 2764
- Comments to the National Quality Forum on African American Heart Failure Measure MUC 16-74
- Jan 25 Value Letter-Administration
- Letter on the Pharmaceutical Information Exchange (PIE) Act of 2017
- Letter to Ways and Means Committee on individual mandate hearing
- Letter of Support for Rep. Price’s nomination as HHS Secretary (Finance)
- Letter of Support for Rep. Price’s nomination as HHS Secretary
- Group Letter on Medicare Non-Interference & Importation
December 2016
